SCHEMBL21177967

SCHEMBL21177967

C=CC(=O)N1CC(C(=O)N2CCN(C(=O)NC3(C#Cc4ccc(Cl)c(Cl)c4)CC3)CC2)C1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCR2 P41597 7/20 0.37
▸ KCNH2 Q12809 7/20 0.37
▸ KRAS P01116 6/20 0.36
▸ OPRK1 P41145 1/20 0.34
▸ ERBB2 P04626 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ EGFR P00533 2/20 0.33
▸ CCR5 P51681 1/20 0.33
▸ CYP3A4 P08684 1/20 0.31
▸ CYP2D6 P10635 1/20 0.31
▸ CYP2C19 P33261 1/20 0.31
▸ TET3 O43151 1/20 0.31
▸ FBXL19 Q6PCT2 1/20 0.31
▸ CXXC5 Q7LFL8 1/20 0.31
▸ KDM2B Q8NHM5 1/20 0.31
▸ CXXC4 Q9H2H0 1/20 0.31
▸ KDM2A Q9Y2K7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21184123 0.90 KMT2A (0.38) KRASOPRK1ERBB2KMT2AMEN1
SCHEMBL21183978 0.86 KMT2A (0.37) KRASOPRK1ERBB2KMT2AMEN1
SCHEMBL21177822 0.84 EPHX2 (0.39) CCR2KCNH2KMT2AMEN1
Hydrochloric Acid SCHEMBL21177399 0.83 CCR2 (0.36) CCR2KCNH2KMT2AMEN1NPC1
SCHEMBL21184078 0.82 KRAS (0.37) KRASERBB2KMT2ATET3FBXL19
SCHEMBL21182293 0.80 LMNA (0.35) KMT2AMEN1NPC1RAB9A
SCHEMBL21184121 0.80 LMNA (0.41) CCR2KCNH2KMT2AMEN1NPC1
SCHEMBL25804233 0.79 GPR183 (0.37) CCR2KCNH2KMT2AMEN1NPC1
SCHEMBL28479106 0.79 GPR183 (0.35) KMT2AMEN1NPC1RAB9AEGFR
SCHEMBL21183980 0.79 KRAS (0.40) KCNH2KRASERBB2KMT2AEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210847-A1 Substituted Alkynylene Compounds As Anticancer Agents AURIGENE ONCOLOGY LTD (IN) 2023-07-06 — — US disclosed
US-20230210847-A1 Substituted Alkynylene Compounds As Anticancer Agents AURIGENE ONCOLOGY LTD (IN) 2023-07-06 — — US disclosed
US-20210379055-A1 Substituted Alkynylene Compounds As Anticancer Agents AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2021-12-09 — — US disclosed
EP-3740473-A1 SUBSTITUTED ALKYNYLENE COMPOUNDS AS ANTICANCER AGENTS Aurigene Discovery Technologies Limited (IN) 2020-11-25 — — EP disclosed
WO-2019142126-A1 SUBSTITUTED ALKYNYLENE COMPOUNDS AS ANTICANCER AGENTS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2019-07-25 — — WO disclosed
WO-2019142126-A1 SUBSTITUTED ALKYNYLENE COMPOUNDS AS ANTICANCER AGENTS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2019-07-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210847-A1 Substituted Alkynylene Compounds As Anticancer Agents MCL1, ROS1, MKI67 CCR2 2291/4885KCNH2 4475/4885KRAS 24/4885
US-20210379055-A1 Substituted Alkynylene Compounds As Anticancer Agents MCL1, ROS1, MKI67 CCR2 2291/4885KCNH2 4475/4885KRAS 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback